Introduction
Ovarian cancer cannot be prevented with complete certainty, because several of the strongest influences on risk are tied to inherited biology, age, and reproductive history rather than a single modifiable exposure. For many people, the practical goal is risk reduction rather than absolute prevention. That distinction matters because ovarian cancer is not one disease with one cause; it includes several tumor types that arise through different biological pathways, some from the ovary itself and others from nearby tissue such as the fallopian tube.
Risk reduction strategies work by lowering the number of times cells are exposed to damaging signals, decreasing chronic inflammation, limiting ovulation-related injury, or reducing the activity of cancer-promoting hormones and genetic pathways. In some high-risk situations, the risk reduction can be substantial. In others, the effect is modest. The best approach depends on a person’s inherited factors, age, reproductive history, and whether there is a known hereditary cancer syndrome.
Understanding Risk Factors
The main risk factors for ovarian cancer fall into several broad categories. One of the most important is genetic susceptibility. Inherited mutations in genes such as BRCA1 and BRCA2 greatly increase lifetime risk, and variants in other DNA repair genes can also raise risk. These genes normally help repair damaged DNA. When they do not function properly, cells can accumulate mutations more easily, allowing malignant transformation to occur.
Age is another important factor. Ovarian cancer becomes more common after menopause, which suggests that cumulative lifetime exposure to cell division, hormonal signaling, and DNA damage plays a role. A longer period of reproductive cycling also means more episodes of ovulation and repair of the ovarian surface or nearby tissue.
Reproductive history influences risk because pregnancy, breastfeeding, and use of hormonal contraception reduce the number of ovulatory cycles. Fewer ovulations appear to lower cancer risk, likely by reducing repeated tissue disruption and repair. In contrast, never having been pregnant or having a shorter duration of breastfeeding may be associated with a higher risk profile.
Other factors include endometriosis, which is linked to certain ovarian cancer subtypes, especially some clear cell and endometrioid tumors. Endometriosis creates a chronic inflammatory environment, with repeated tissue injury, immune signaling, and local iron-related oxidative stress. Family history is also important even when no specific mutation has been identified, because it may reflect shared genes or inherited patterns of risk.
Body weight, diabetes, and some hormonal exposures may contribute indirectly through inflammation, insulin signaling, and estrogen-related effects, although their influence is smaller and less direct than the effect of high-penetrance inherited mutations. Fertility treatment has been studied extensively, but the evidence does not show a large independent increase in risk when underlying infertility is taken into account.
Biological Processes That Prevention Targets
Prevention strategies aim at the biological steps that make ovarian cancer more likely to develop. One major target is ovulation-related injury. Each ovulation causes a small rupture and repair process in ovarian and adjacent tubal tissue. Repeated repair cycles increase cellular turnover, and with more cell division comes more opportunity for DNA errors. Reducing the number of ovulations may therefore reduce cumulative tissue injury and mutation accumulation.
Another target is hormonal stimulation. Estrogen and progesterone influence cell growth, differentiation, and signaling in reproductive tissues. Some risk-reducing strategies alter the balance of these hormones or reduce the number of hormone-driven cycles. This may limit the proliferative environment in which premalignant clones can expand.
A third process is DNA damage repair. In people with inherited defects in BRCA or related genes, cells are less able to repair double-strand DNA breaks. Cancer prevention in these groups often focuses on removing tissue at highest risk, rather than relying only on lifestyle change, because the underlying repair problem remains present in all cells.
Inflammation also matters. Chronic inflammatory signaling can promote cell survival, increase oxidative stress, and encourage mutations. Conditions such as endometriosis, obesity, and some metabolic disorders may create a local or systemic environment that supports tumor initiation or progression. Risk reduction strategies therefore include interventions that reduce chronic inflammation or its consequences.
Lifestyle and Environmental Factors
Lifestyle factors have a smaller effect on ovarian cancer risk than inherited susceptibility, but they can still influence the biological environment in which cancer develops. Body weight is one example. Excess adipose tissue increases estrogen production after menopause and is associated with chronic low-grade inflammation, insulin resistance, and altered levels of growth-related hormones. These changes can support abnormal cell growth in multiple tissues, including the ovary and fallopian tube.
Physical inactivity may contribute indirectly through its effects on body weight, insulin signaling, and inflammatory tone. In contrast, regular activity is associated with a more stable metabolic profile, although its specific protective effect for ovarian cancer is less clearly defined than for some other cancers.
Tobacco exposure is more strongly linked to certain ovarian tumor subtypes than to ovarian cancer overall. Cigarette smoke contains carcinogens that can form DNA adducts and generate oxidative damage. Because different ovarian cancers arise from different cells and pathways, tobacco may influence some histologic types more than others.
Environmental exposures have been studied, including talc and some industrial chemicals, but the evidence for many of these associations is inconsistent. The strongest environmental influences remain those that affect hormones, metabolism, and chronic inflammation rather than a single external toxin. Diet has not been shown to prevent ovarian cancer directly, although dietary patterns that help maintain healthy metabolic function may contribute indirectly to risk reduction.
Medical Prevention Strategies
Medical prevention is most important for people at elevated inherited risk. Hormonal contraception, especially combined oral contraceptives, is one of the best-studied risk-reducing measures. By suppressing ovulation, these medications lower the number of ovulatory cycles and reduce repetitive ovarian and tubal epithelial injury. The protective effect increases with longer use and can persist for years after stopping.
Tubal ligation and other forms of salpingectomy are also associated with lower ovarian cancer risk. This finding supports the current understanding that many high-grade serous cancers may begin in the fallopian tube rather than the ovary itself. Removing or disrupting the tube may reduce the chance that precancerous cells spread to the ovary or pelvic cavity.
For individuals with a strong hereditary predisposition, especially BRCA1 or BRCA2 mutation carriers, risk-reducing salpingo-oophorectomy is the most effective preventive surgery. This operation removes the fallopian tubes and ovaries, sharply reducing the tissue at highest risk of malignant transformation. It can substantially lower ovarian and fallopian tube cancer incidence, although it may also trigger surgical menopause if performed before natural menopause.
Some people at high risk may consider opportunistic salpingectomy during other pelvic surgery. This approach removes the tubes while preserving the ovaries when appropriate, aiming to reduce risk without immediately causing menopause. Its protective effect is based on the growing evidence that the fallopian tube is a common origin site for certain ovarian cancers.
Chemoprevention with agents such as aspirin or other anti-inflammatory drugs has been studied, but evidence is not strong enough for routine use solely to prevent ovarian cancer. Likewise, supplements have not been proven to meaningfully lower risk. In high-risk families, the most effective medical strategies are usually genetic counseling, targeted surveillance, and surgery when indicated.
Monitoring and Early Detection
Monitoring cannot fully prevent ovarian cancer, but it can help identify risk earlier and guide preventive decisions. This is especially relevant for people with hereditary cancer syndromes, strong family history, or prior gynecologic conditions associated with elevated risk. Genetic testing is a key part of monitoring in these groups because it clarifies whether a person carries a mutation that would justify more intensive prevention.
Routine screening of the general population has not been shown to reduce ovarian cancer deaths. Tests such as transvaginal ultrasound and CA-125 blood testing can detect abnormalities, but they also produce false positives and do not reliably find disease early enough to change outcomes for average-risk individuals. For this reason, screening is not considered a universal prevention strategy.
In people with known high risk, periodic evaluation may still have value as a bridge to definitive prevention. Monitoring can support decisions about the timing of risk-reducing surgery and can identify concerning changes that warrant further investigation. The biological rationale is not that screening eliminates the cancer process, but that it may shorten the time between emergence of abnormal tissue and diagnosis.
Early detection is especially important because ovarian cancer often spreads before symptoms are specific. Once cancer is advanced, prevention is no longer the goal; the focus shifts to treatment. Thus, monitoring is best understood as a risk-management tool rather than true prevention.
Factors That Influence Prevention Effectiveness
Prevention is not equally effective for everyone because ovarian cancer risk is shaped by different biological mechanisms in different people. A person with a BRCA1 mutation has a much larger inherited risk than someone whose risk is related mainly to reproductive history or body weight. In the first case, removing high-risk tissue may provide large benefit. In the second, hormonal or lifestyle-related measures may offer a more modest relative reduction.
Age and menopausal status also affect which strategies are practical. Hormonal contraception may be useful earlier in life, while salpingectomy or oophorectomy may be more relevant after childbearing is complete or when the inherited risk is substantial. Before menopause, ovary removal has important consequences for hormone levels and long-term health, which influences how preventive surgery is timed.
The specific tumor subtype matters as well. High-grade serous cancers are more strongly linked to the fallopian tube, whereas some endometrioid and clear cell tumors are associated with endometriosis. Because the initiating tissue and molecular pathways differ, a strategy that lowers risk for one subtype may have a smaller effect on another.
Personal reproductive goals, prior surgeries, and existing medical conditions also shape prevention. For example, someone who already had a tubal ligation may have lower risk than someone who has not. Someone with obesity or insulin resistance may benefit more from measures that improve metabolic status than from approaches focused only on ovulation suppression.
Finally, the balance between benefit and harm influences how effective a prevention strategy is in practice. A highly protective intervention may still be unsuitable if it creates significant adverse effects, while a modest intervention may be useful if it is low risk and compatible with the person’s overall health situation.
Conclusion
Ovarian cancer is not fully preventable in the absolute sense, but risk can often be reduced through a combination of genetic assessment, reproductive and hormonal factors, lifestyle management, and in some cases preventive surgery. The main biological targets are repeated ovulation, hormonal stimulation, inflammation, and impaired DNA repair. These processes help explain why hormonal contraception, tubal procedures, and risk-reducing salpingo-oophorectomy can lower risk in selected people.
The most effective prevention depends on the source of risk. For average-risk individuals, the effect of lifestyle and reproductive factors is usually modest. For people with inherited mutations such as BRCA1 or BRCA2, medical prevention can be much more important and more effective. Monitoring and genetic evaluation do not prevent all cases, but they help identify who benefits most from stronger preventive measures. In practice, ovarian cancer risk reduction is best understood as a biologically informed combination of strategies rather than a single universal intervention.